Information Provided By: 
Fly News Breaks for September 14, 2017
RARE
Sep 14, 2017 | 06:59 EDT
Wedbush analyst David Nierengarten upgraded Ultragenyx to Outperform from Neutral, stating that the favorable reception to the company's presentations and the feedback he received from discussions at the ASBMR conference leave him more positive on the uptake of burosumab. The analyst, who thinks negative sentiment on Ultragenyx shares has probably peaked following the recent Phase 3 failure of its Ace-ER program, has a $62 price target on the shares.
News For RARE From the Last 2 Days
